Clinical Guidelines for Recurrent Fever Syndromes

Abstract

Recurrent fever syndromes encompass a heterogeneous group of autoinflammatory and infectious disorders characterized by repeated episodes of unexplained fever, frequently posing diagnostic and management challenges for clinicians. This review synthesizes recent evidence and guideline-based recommendations, offering a comprehensive overview of epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, and management strategies. Special attention is devoted to advances in molecular diagnostics, emerging targeted therapies, and practical clinical implications, aiming to equip healthcare professionals with the knowledge required for optimal patient care.

Introduction

Recurrent fever syndromes, also termed periodic fever syndromes, are defined by the presence of multiple febrile episodes separated by symptom-free intervals, with no clear infectious or malignant etiology. These syndromes are of growing clinical relevance due to increasing recognition of their genetic and immunological underpinnings, and the significant morbidity they impose when inadequately managed. Clinicians must differentiate autoinflammatory conditions such as Familial Mediterranean Fever (FMF), Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), and Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis (PFAPA) from infectious, malignant, and autoimmune etiologies, employing a multidisciplinary, evidence-based approach.

Epidemiology / Disease Burden

The true prevalence of recurrent fever syndromes is likely underestimated due to diagnostic delays and overlap with more common infectious causes. FMF is most prevalent in populations from the eastern Mediterranean, with carrier rates up to 1:5 in certain ethnic groups. TRAPS and Mevalonate Kinase Deficiency (MKD) are rare but increasingly recognized in Europe and North America. PFAPA is the most common pediatric recurrent fever syndrome, with an estimated incidence of 2.3 per 10,000 children under five. These syndromes contribute substantially to healthcare utilization, missed school and work days, and, in the case of hereditary syndromes, can lead to severe complications such as amyloidosis if untreated.

Pathophysiology

Autoinflammatory recurrent fever syndromes result from dysregulated innate immune responses, often linked to genetic mutations affecting inflammasome components or cytokine signaling pathways. For instance, FMF is caused by mutations in the MEFV gene encoding pyrin, leading to excessive interleukin-1β (IL-1β) production. In TRAPS, mutations in the TNFRSF1A gene impair tumor necrosis factor (TNF) receptor function, resulting in unrestrained inflammation. MKD involves a deficiency in mevalonate kinase, disrupting isoprenoid biosynthesis and promoting cytokine release. PFAPA, while not linked to monogenic mutations, is hypothesized to involve aberrant tonsillar immune responses. Understanding these mechanisms is crucial for rational therapeutic targeting and disease monitoring.

Risk Factors

Genetic predisposition is the principal risk factor for hereditary recurrent fever syndromes. Homozygous or compound heterozygous mutations, as seen in FMF or MKD, significantly increase disease risk and severity. Ethnic background, particularly Mediterranean, Middle Eastern, and North African descent, is associated with higher prevalence of FMF. Environmental triggers such as infections, stress, and temperature fluctuations may precipitate episodes in susceptible individuals. A positive family history is frequently reported in monogenic syndromes, whereas PFAPA typically lacks a genetic pattern.

Clinical Features

Recurrent fever syndromes share the hallmark of abrupt-onset fever episodes, but each entity presents with distinctive associated symptoms. FMF often features serositis (peritonitis, pleuritis), arthritis, and erysipeloid rash. TRAPS is characterized by prolonged fever, migratory myalgias, abdominal pain, and periorbital edema. MKD presents with fever, lymphadenopathy, rash, and gastrointestinal symptoms. PFAPA involves regular febrile episodes with aphthous stomatitis, pharyngitis, and cervical adenitis, predominantly in children. Intervals between episodes are typically asymptomatic. Chronic complications may include amyloidosis, particularly in untreated FMF, and growth impairment in pediatric cases.

Diagnosis

Diagnosis requires careful exclusion of infectious, malignant, and autoimmune causes. A thorough history, including episode frequency, associated features, ethnic background, and family history, is essential. Laboratory findings often reveal elevated inflammatory markers (CRP, ESR, SAA) during attacks but normalize between episodes. Genetic testing is pivotal for confirming monogenic autoinflammatory syndromes and guiding management. In PFAPA, diagnosis is clinical, based on established criteria and exclusion of alternative causes. Imaging may be warranted to evaluate organ involvement or exclude complications. Emerging molecular diagnostics, including next-generation sequencing panels, have improved diagnostic yield for atypical or overlapping presentations.

Treatment & Management

Management strategies are tailored to the specific syndrome and disease severity. Colchicine remains the mainstay of FMF therapy, effectively preventing attacks and reducing amyloidosis risk. In colchicine-resistant or intolerant cases, IL-1 inhibitors (anakinra, canakinumab) offer significant benefit. TRAPS and MKD frequently require biologic agents targeting IL-1 or TNF pathways. PFAPA responds well to single-dose corticosteroids during episodes, though tonsillectomy may be considered for refractory cases. Supportive care, regular monitoring, and multidisciplinary collaboration are essential for optimizing outcomes. Patient education on disease triggers, adherence, and genetic counseling form integral components of comprehensive care.

Recent Advances / Emerging Therapies

The advent of targeted biologic therapies has revolutionized management of refractory recurrent fever syndromes. IL-1 blockade, with agents such as canakinumab, has demonstrated efficacy in FMF, TRAPS, and MKD, leading to sustained remission in many cases. TNF inhibitors and IL-6 antagonists are under investigation for selected patients. Advances in genetic testing, including whole exome sequencing, facilitate early and accurate diagnosis, particularly in atypical or overlapping cases. Ongoing trials aim to refine therapeutic protocols, optimize dosing, and reduce long-term complications. Personalized medicine approaches, integrating genetic, molecular, and clinical data, hold promise for future care paradigms.

Guideline Recommendations

Recent consensus guidelines from international rheumatology and immunology societies emphasize early recognition, genetic confirmation, and individualized management. Colchicine is strongly recommended as first-line therapy for FMF, with IL-1 inhibitors reserved for refractory cases. Biologic therapy is advised for TRAPS and MKD unresponsive to conventional agents. PFAPA guidelines endorse corticosteroid pulses as effective abortive therapy, with tonsillectomy as a second-line option. Regular monitoring for complications, adherence to therapy, and patient/family education are universally endorsed. Genetic counseling is recommended for affected families, particularly in populations with high carrier frequencies.

Conclusion

Recurrent fever syndromes represent a diagnostically and therapeutically challenging group of disorders with significant clinical implications. Advances in molecular genetics, immunopathology, and biologic therapies have transformed the management landscape, enabling more precise diagnosis and targeted interventions. Adherence to evidence-based clinical guidelines, coupled with multidisciplinary collaboration and patient-centered care, is essential for optimizing outcomes and preventing long-term complications. Ongoing research will further elucidate disease mechanisms and inform future therapeutic innovations, ultimately improving quality of life for affected individuals.